Opus Genetics Reports $7.4 Million Net Loss in Q2 2025, Revenue from Collaborations Increases

Opus Genetics, Inc. reported a net loss of $7.4 million for the three months ended June 30, 2025, a slight improvement from a net loss of $7.8 million during the same period in 2024. For the six months ended June 30, 2025, the company recorded a net loss of $15.6 million, compared to a loss of $14.9 million in the prior year. The increase in losses was primarily attributed to higher operating expenses, which rose to $26.1 million from $18.9 million year-over-year. The company's revenue from license and collaborations surged to $2.9 million in Q2 2025, up from $1.1 million in Q2 2024, driven by increased research and development services under the Viatris License Agreement.

Total operating expenses for the second quarter of 2025 were $11.8 million, compared to $9.4 million in the same quarter of 2024. General and administrative expenses accounted for a significant portion of this increase, rising to $5.8 million from $3.4 million, largely due to public company-related costs and legal expenses. Research and development expenses remained relatively stable, totaling $6.0 million in Q2 2025, down slightly from $6.1 million in Q2 2024. The company’s accumulated deficit as of June 30, 2025, stood at $154.6 million.

In terms of strategic developments, Opus Genetics completed the acquisition of Private Opus in October 2024, significantly expanding its product pipeline, which now includes gene therapies targeting inherited retinal diseases. The company has also made progress with its lead gene therapy candidate, OPGx-LCA5, which is currently in a Phase 1/2 clinical trial. The therapy has shown promising results, with initial data indicating visual improvement in treated patients. Additionally, the company received FDA approval for its Phentolamine Ophthalmic Solution 0.75%, branded as RYZUMVI, which was launched commercially in April 2024.

Operationally, Opus Genetics reported a cash position of $32.4 million as of June 30, 2025, an increase from $30.3 million at the end of 2024. The company anticipates that its current cash reserves will be sufficient to fund operations for at least the next twelve months. The company’s workforce has also expanded, with an increase in employee headcount to support ongoing clinical trials and product development efforts. Looking ahead, Opus Genetics plans to continue advancing its clinical programs and may seek additional funding through equity or debt financing to support its growth initiatives.